Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumorsRobert Svensson, Peter J. Tummino, Justin A. Caravella et al.|Cancer Research|2025Cited by 5
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumorsScott Boiko, Robert Svensson, Di Li et al.|European Journal of Cancer|2024Cited by 0
Knowledge andStructure-Based Drug Design of 15-PGDHInhibitorsLeela S. Dodda, Neelu Kaila, Sébastien Campos et al.|Journal of Medicinal Chemistry|2025Cited by 0